GW
KPTI icon

GW & Wade’s Karyopharm Therapeutics KPTI Stock Holding History

GW & Wade’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$39K Hold
3,009
– – ﹤0.01% 405
2023
Q3 		$60K Buy
+3,009
New +$67.5K ﹤0.01% 398

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GW & Wade's KPTI Position: Q4 2023 in Review

GW & Wade held its Karyopharm Therapeutics (KPTI) position steady in Q4 2023 at 3,009 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #405.

GW & Wade first reported a position in KPTI in Q3 2023 and has held it in 2 quarters since. The position peaked at $60K in Q3 2023. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

  • GW & Wade held 3,009 shares of Karyopharm Therapeutics worth $39K as of Q4 2023.
  • GW & Wade left its Karyopharm Therapeutics share count unchanged in Q4 2023.
  • Karyopharm Therapeutics made up ﹤0.01% of GW & Wade's portfolio in Q4 2023, its #405 holding.
  • GW & Wade first reported a position in Karyopharm Therapeutics in Q3 2023 and has held it in 2 quarters since.
  • GW & Wade's Karyopharm Therapeutics position peaked at $60K in Q3 2023.
  • 117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on GW & Wade's 13F filing for Q4 2023, filed 8 Feb 2024.